- Home
- SQFT vs NEUP Comparison
SQFT vs NEUP Comparison
Compare SQFT & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SQFT
- NEUP
- Stock Information
- Founded
- SQFT 1999
- NEUP 1996
- Country
- SQFT United States
- NEUP United States
- Employees
- SQFT N/A
- NEUP N/A
- Industry
- SQFT Real Estate Investment Trusts
- NEUP
- Sector
- SQFT Real Estate
- NEUP
- Exchange
- SQFT Nasdaq
- NEUP Nasdaq
- Market Cap
- SQFT 8.1M
- NEUP 9.3M
- IPO Year
- SQFT 2020
- NEUP N/A
- Fundamental
- Price
- SQFT $0.63
- NEUP $5.19
- Analyst Decision
- SQFT
- NEUP Strong Buy
- Analyst Count
- SQFT 0
- NEUP 1
- Target Price
- SQFT N/A
- NEUP $21.00
- AVG Volume (30 Days)
- SQFT 39.3K
- NEUP 28.4K
- Earning Date
- SQFT 05-13-2025
- NEUP 05-15-2025
- Dividend Yield
- SQFT N/A
- NEUP N/A
- EPS Growth
- SQFT N/A
- NEUP N/A
- EPS
- SQFT N/A
- NEUP N/A
- Revenue
- SQFT $18,925,275.00
- NEUP $662,715.00
- Revenue This Year
- SQFT $23.63
- NEUP N/A
- Revenue Next Year
- SQFT N/A
- NEUP N/A
- P/E Ratio
- SQFT N/A
- NEUP N/A
- Revenue Growth
- SQFT 7.31
- NEUP N/A
- 52 Week Low
- SQFT $0.47
- NEUP $2.12
- 52 Week High
- SQFT $1.00
- NEUP $15.24
- Technical
- Relative Strength Index (RSI)
- SQFT 54.11
- NEUP N/A
- Support Level
- SQFT $0.62
- NEUP N/A
- Resistance Level
- SQFT $0.68
- NEUP N/A
- Average True Range (ATR)
- SQFT 0.03
- NEUP 0.00
- MACD
- SQFT 0.01
- NEUP 0.00
- Stochastic Oscillator
- SQFT 69.55
- NEUP 0.00
About SQFT Presidio Property Trust Inc.
Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located primarily in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.